iPSC generation & genome editing · Leuven, Belgium
Your desired genetic code, in the stem cells you need.
We accelerate your research with iPSC reprogramming and CRISPR genome editing, delivered by the scientists of the Stem Cell Institute Leuven (KU Leuven).
- Founded by scientists of the Stem Cell Institute Leuven, KU Leuven
- Based at Bio-Incubator Leuven
- Partner in Interreg Project FIT
Our services
From patient cells to precisely edited iPSC lines
iPSC generation
Reprogramming of fibroblasts, PBMCs, urine-derived or epithelial cells with non-integrating Sendai virus; mRNA reprogramming on request.
Explore iPSC generationGenome editing
CRISPR-Cas9 delivered as RNP for single-nucleotide changes, knock-ins and knockouts – homozygous or heterozygous.
Explore genome editingFree consultation
A no-obligation call with our scientists to plan or refine the experimental design of your project.
Book a call
Track record of ReWrite scientists at the Stem Cell Institute Leuven
- studies demonstrating our expertise
- 41+
- genetically edited stem cells
- 106+
- reprogrammed iPSC lines
- 62+
Published in Nature Communications · Nature Protocols · Stem Cell Reports · Brain · EMBO Journal · The CRISPR Journal
Who we are
Two decades of stem cell know-how, now as a service
ReWrite was founded by scientists from the Stem Cell Institute Leuven (SCIL), established at KU Leuven in 2005. Led by Prof. em. Catherine Verfaillie and Dr. Arefe Nami, we bring that expertise in reprogramming and genome editing to your project.
- Expert-driven, efficient and affordable
- Streamlined process with minimum time-to-results
- Comprehensive quality control and consistent, reliable results
- Tailored to your needs through in-depth scientific discussion
Project FIT · Muscle stem cell therapy
Within the Euregio Meuse-Rhine, ReWrite works with leading universities and innovative companies in Maastricht, Leuven, Liège, Hasselt and Aachen on Project FIT (IMR6-00132). Together we are advancing personalised therapies using patient-derived muscle stem cells to treat rare disorders, age-related muscle loss and heart disease. The project is co-funded by the European Union and the Walloon Region.
Planning an iPSC or genome editing project?
Tell us what you need – we are happy to discuss your project.